CARLSBAD, Calif., Oct. 11 /PRNewswire-FirstCall/ -- The following
letter is being released by The Immune Response Corporation (OTC Bulletin
Board: IMNR) to its shareholders. It is also available online at
http://www.imnr.com/ir/ir.htm.
October 11, 2006
Dear Shareholders,
As I approach my first anniversary as President and CEO of The Immune
Response Corporation, I am delighted to report that the Company has made
tremendous progress during the last year in pursuit of a revamped and
reinvigorated corporate and clinical strategy. Our strategy was designed to
position IRC for long-term success by accelerating the development of our
most promising immune-based therapies: NeuroVax(TM) for multiple sclerosis
(MS) and IR103 for HIV/AIDS. It was the significant potential impact and
value of these therapies that attracted me to step away from my position at
the White House and join IRC in the first place. Both of our candidate
vaccines have the potential to offer the following important clinical
advances to patients suffering from these devastating diseases:
* A highly targeted means to mobilize their immune system to control the
mechanism of disease;
* A new therapeutic option that can potentially be used early and
throughout the course of disease alone and in conjunction with other
therapies; and
* An attractive infrequent dosing regimen that to date shows no
substantial system side effects.
I see both products at the vanguard of 21st century medicine - they are
highly targeted, potentially less toxic medicines that harness the body's
own defenses to control and prevent disease. The possibilities of this type
of treatment are well portrayed in an article from this month's issue of
Scientific American called "Peacekeepers of the Immune System" which
details the role of FoxP3+ T Regulatory cells, the same cells our product,
NeuroVax(TM) has been shown to stimulate in MS patients.
Through focused effort by our team and with meaningful financial
support from our shareholders, we have begun to make important strides
toward realizing the potential of our products. The purpose of this update
is to highlight our accomplishments as well as provide insights into our
future plans. I also hope to convey our enthusiasm and firm belief that IRC
is now headed in the right direction. I, my team and our Board of Directors
are convinced that we have made the right strategic choices so far. We are
committed to rigorous science and believe the completion of robust clinical
trials for our products offers the most viable path to success.
Despite our conviction and our progress, we remain frustrated by the
performance of our stock and believe our share price does not nearly
reflect the current and potential value of our company. This gap in value
is, of course, the crux of the opportunity for investors that have recently
purchased our stock or are considering doing so in the near future. We
intend to continue to execute our clinical, commercial and communications
plans and, in doing so, strive to build substantial value for our
shareholders.
Accomplishments
The last seven months have been highly productive. We have raised
capital, presented new data and advanced the clinical programs for both
products, as well as demonstrated dramatic yield improvements at our
manufacturing facility. The key milestones we have hit during this active
period are:
Financing
* Raised $17.9 million through the completion of a private placement in
February/March and the exercise of warrants between June and August
Multiple Sclerosis -- NeuroVax(TM)
* Organized clinical investigators at sites in 12 European countries for
patient enrollment to begin before year end for our 200-patient Phase
IIb trial of NeuroVax(TM)
* Secured key partnerships with a leading MS clinical research
organization (CRO) and outstanding MRI analysis facility to oversee and
support our Phase IIb NeuroVax(TM) trial
* Established a prestigious MS scientific advisory board composed of key
opinion leaders who are now active in helping guide the development of
NeuroVax(TM)
* Presented new Phase II data at the American Academy of Neurology (AAN)
meeting demonstrating the ability of NeuroVax(TM) to restore MS
patients' FOXP3+ regulatory T-cell levels which are believed to help
control disease progression
HIV/AIDS -- IR103
* Completed the first stage of enrollment of anti-retroviral naïve
patients (55 new patients, 31 returning patients) in our Phase II trial
of IR103 in Italy
* Announced approval to expand our Phase II trial of IR103 in Italy to
include clinical sites in France as well as an additional 50 patients
* Presented preliminary Phase II data at the ISHEID conference
demonstrating IR103's ability to enhance HIV-specific immune responses
in drug naive patients
Manufacturing
* Announced an at least two-fold increase in HIV antigen production
yields using new, optimized manufacturing processes
The remainder of this year and 2007 are shaping up to be even more
eventful.
Multiple Sclerosis -- NeuroVax(TM)/Autoimmune Diseases
The imminent launch of our 200-patient Phase IIb trial of NeuroVax(TM)
will be a watershed event for our company. The milestones we announced
yesterday are the product of months of enormous effort by our management
team to assemble and coordinate all of the resources we need to properly
carry out this significant trial. We carefully selected Accelsiors, a CRO
with an outstanding track record with Multiple Sclerosis Phase II trials.
We recruited clinical investigators at sites in 12 Eastern and Central
European countries selected because they offer some of the only
sophisticated locations remaining with sufficient numbers of diagnosed but
untreated MS patients, MRI capabilities needed to conduct sound research
and which also allow placebo- controlled studies. We are now completing all
of the regulatory processes and product shipments to get these sites ready
for patient enrollment and will hold a kick-off meeting for our
investigators in Budapest, Hungary in November. Patient enrollment of the
multi-center, randomized, double-blind trial is set to begin shortly
thereafter.
Successful completion of this trial has the potential to put our
technology center stage in the battle against MS and other autoimmune
diseases. The 200-patient trial will test the clinical benefits of one year
of treatment with NeuroVax(TM) versus a placebo. The primary endpoint of
the trial is cumulative new brain lesions as shown by MRI (magnetic
resonance imaging), but the trial will also track patients' relapse rates
and neurological performance. All of these data will give us a thorough
profile of the potential efficacy of NeuroVax(TM), enabling us to pursue a
significant partnership to commercialize this product.
FOXP3+ Highlighted in latest issue of Scientific American
This large NeuroVax(TM) trial will also give us the opportunity to
further explore the FOXP3+ regulatory T-cell mechanism of action that was
demonstrated in our Phase IIa trial data presented this past April at AAN.
As evidenced by the article entitled "Peacekeepers of the Immune System" in
the latest issue of Scientific American, the role of FOXP3+ regulatory
T-cells in controlling autoimmune disease has become a very important topic
in immunology in the last 18 months. To our knowledge, NeuroVax(TM) is the
first therapeutic that has been shown in clinical trials to boost FOXP3+
levels in patients with MS. Our new trial will generate substantial
additional data related to this mechanism which we hope will help
scientists better understand the potential for NeuroVax(TM) to alter the
course of MS by amplifying FOXP3+ responses.
Beyond MS, we believe that our approach that impacts on the FOXP3+
immune regulatory mechanism could well prove to be a major breakthrough for
autoimmune disease in general including psoriasis and rheumatoid arthritis
(RA) for which we have TCR peptide-based therapeutic vaccines (Zorcell(TM)
for psoriasis and RaVax(TM) for RA) with Investigational New Drug
Applications with the FDA. During the next year, we plan to initiate new
clinical work with at least one of these products aimed at evaluating the
effect on FOXP3+. This work will expand our autoimmune product pipeline and
position us to further exploit the potential of our intellectual property
position with respect to clinical applications of vaccines and diagnostics
that impact FOXP3+.
HIV/AIDS -- IR103
Recent HIV/AIDS studies indicate that a patient's CD4+ count is the
most significant marker of HIV disease progression. An immune based therapy
like IR103 that can impact CD4+ count may well be an enormous contribution
to the current treatment landscape.
Between now and the end of the year, we intend to complete enrollment
of over 200 antiretroviral drug-naive patients in our expanded Phase II
clinical trials of IR103 in Italy, France, the United Kingdom, and Canada.
These trials, for which we have already enrolled over 100 patients, are
designed to run one year and give us a robust clinical and immunological
profile of IR103. We plan to leverage these data to design pivotal trials
of this product and to help drive new collaborations to support our global
development program. We hope to have interim results from these open label
Phase II clinical trials soon, which will provide important data regarding
the impact of IR013 on CD4+ counts and other important markers.
In the meantime, our team has been hard at work building and, in some
cases, reestablishing relationships with key HIV/AIDS clinicians,
scientists and activists. I am encouraged by the reception we have garnered
so far to our new vaccine candidate and revised clinical strategy.
Increasing numbers of people in the HIV/AIDS community are beginning to
understand that the "whole, inactivated" HIV antigen concept -- our
technology -- has not been explored enough either as a therapeutic or
preventive vaccine. We are intent on building upon this support to gather
scientific, clinical and financial assistance for our product development
efforts. I am optimistic that we will be able to share some of the first
meaningful signs of this added support over the course of the next year.
The Future
Our products -- NeuroVax(TM) and IR103 -- are potential breakthroughs
in the treatment of MS and HIV/AIDS. Our objective over the next 18-24
months is to provide robust clinical evidence of this potential that we can
leverage to build substantial shareholder value and enable our company to
advance these products toward commercialization. Looking ahead, we have set
clear goals for this critical period which include:
* Completing patient enrollment for our Phase II clinical trials on
schedule
* Presenting interim results from open label IR103 trials at scientific
forums throughout 2007
* Securing an appropriate level of financing to facilitate the execution
of our strategic plans
* Completing our Phase II clinical trials and presenting final results in
accordance with rigorous scientific standards
* Executing public and private partnerships to expedite the further
development of our products
Achieving our goals will depend both on clinical and commercial
execution and on the continued financial transformation of our company.
This year's financing transactions have dramatically reshaped our
capitalization and several additional steps remain to be completed before
we can optimize IRC's appeal to the broadest base of potential investors.
These include:
* Generating maximum proceeds from the exercise of the final tranche of
2006 Private Placement warrants prior to their expiration on
November 30, 2006;
* Completing an appropriate and well-timed reverse stock split; and
* Qualifying for re-listing on a major stock exchange.
As you are likely aware, we received shareholder approval for a reverse
stock split of up to 1-for-100 last April. Such a reverse split will be a
critical step in increasing IRC's appeal to institutional investors as well
as enabling us to qualify for re-listing. While we are committed to
completing this course of action at the appropriate time, we are even more
committed to protecting shareholder value through and after the process. We
remain cautious and thoughtful about this step, and plan to effectuate it
in the context of complementary achievements and events to generate the
most positive outcome.
Overall, I am very encouraged by the progress we have made and with the
outlook for our future. While I am disappointed that our success and
potential are not reflected in our share price, I continue to believe that
the market will ultimately recognize the true value of IRC and that current
shareholders will be rewarded for their support, patience and prescience. I
offer my sincere gratitude to our shareholders who provided necessary
capital in support of our efforts through their participation in the
private placement of our securities in February and March and by exercising
their warrants this summer. I am hopeful that this financial support will
continue as we approach the 45-day exercise period of the final $12 million
tranche of warrants. I, along with my management team and Board of
Directors, remain firmly committed to fully executing our plan, actively
communicating with you and creating substantial shareholder value through
our success.
Sincerely,
Joseph O'Neill, MD, MPh
Chief Executive Officer and President
This letter contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could,
will, might, plan, projection, forecast, expect, guidance, potential and
developing. Actual results could vary materially from those expected due to
a variety of risk factors, including whether the Company will continue as a
going concern and successfully raise proceeds from financing activities
sufficient to fund operations and additional clinical trials of
NeuroVax(TM) or IR103, the uncertainty of successful completion of any such
clinical trials, the fact that the Company has not succeeded in
commercializing any drug, the risk that NeuroVax(TM) or IR103 might not
prove to be effective as either a therapeutic or preventive vaccine,
whether future trials will be conducted and whether the results of such
trials will coincide with the results of NeuroVax(TM) or IR103 in
preclinical trials and/or earlier clinical trials. A more extensive set of
risks is set forth in The Immune Response Corporation's SEC filings
including, but not limited to, its Annual Report on Form 10-K for the year
ended December 31, 2005, and its subsequent Quarterly Reports filed on Form
10-Q. The Company undertakes no obligation to update the results of these
forward-looking statements to reflect events or circumstances after today
or to reflect the occurrence of unanticipated events.
Remune(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
The Immune Response Corporation (the Company) has filed a registration
statement (including a prospectus) with the SEC for the resale of the
shares underlying its March 2006 private placement, consisting of $8
million of convertible notes, and $24 million of short-term warrants, all
priced at $0.02 per share, plus certain other shares. This prospectus can
be viewed at
http://www.sec.gov/Archives/edgar/data/817785/000093639206000622/a18840b3e424b3.ht
m. Before you invest, you should read the prospectus in that registration
statement and other documents the Company has filed with the SEC for more
complete information about the Company and this offering. You may get these
documents for free by visiting EDGAR on the SEC Web site at http://www.sec.gov.
Alternatively, the Company will arrange to send you the prospectus if you
request it by calling (760) 431-7080.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com/ir/ir.htm
CONTACT:
Media, Stacey Pfeffer of Chamberlain
Communications Group Inc., +1-212-884-0639,
speffer@chamberlainpr.com, for The Immune Response Corporation;
or Investors, Gene Marbach of Makovsky & Company,
+1-212-508-9645, gmarbach@makovsky.com, for The Immune Response
Corporation; or Michael K. Green, COO of The Immune Response
Corporation, +1-760-431-7080, info@imnr.com
|
